Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InSaKa trial
2024-514889-40-00Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin aspart, human insulin, salbutamol and glucose in hyperkalemia (3 arms), sponsored by CHU de Nantes. Primary endpoint: Mean change in absolute serum potassium level from baseline to 60 minutes. Started Jul 2024; status: completed.
02
Drugs
insulin asparthuman insulinsalbutamolglucose
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2024-514889-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514889-40-00.